Leslie Sheffield begins this issue with a report (pp 144–145) on the International Society of Pharmcogenomics’ (ISP) second annual meeting from 2–3 November 2003 in Los Angeles, CA, USA. The conference was held in association with the Pacific Rim Association for Clinical Pharmacogenetics, and presentations focused on the pharmacogenomics of drugs in clinical practice, gene mapping, HapMap developments, and updates on the search for novel drug targets. Speakers included Magnus Ingleman-Sundberg, Urs Meyer, Olivier Grenet, Tamas Bartfai, and others presenting at the conclave's four symposia.
The island of Santorini, Greece played host to the ISP's third annual meeting, entitled ‘From Human Genetic Variations to Prediction of Risks and Responses to Drugs and to the Environment’ (1–4 October 2004). As a collaborative effort with the International Union of Nutritional Sciences, the meeting aimed to bring together clinicians and scientists from academia and industry to discuss how genome variation plays a role in drug response and nutrition. Leslie Sheffield's bulletin (pp 146–148) features session highlights of the broad range of topics discussed, including cardiovascular disease, nutrigenomics, cancer pharmacogenomics, drug targets, neurological disorders and proteomics.
This is a preview of subscription content, access via your institution